Skip to main content
Premium Trial:

Request an Annual Quote

Promega, SignalChem Team on Kinase Profiling Tools

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Promega today announced that it has partnered with SignalChem Pharmaceuticals to offer a combination of their technologies for profiling kinase inhibitors against the human kinome.

The offering will combine SignalChem's Kinase Enzyme Systems with Promega's ADP-Glo Kinase Assay. Madison, Wis.-based Promega said that the combination provides "all of the necessary tools and give[s] drug screeners unprecedented ease to profile inhibitors against the human kinome for off-target effects."

Promega said that its will distribute SignalChem's Kinase Enzyme Systems as a stand-alone enzyme system or in combination with its own ADP-Glo Assay.

Further terms of the alliance were not disclosed.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.